Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase I trial

Neurofibrillary Tangles of Aβx-40 in Alzheimer’s Disease Brains

(2017) Ana-María Lacosta et al.   JOURNAL OF ALZHEIMERS DISEASE

Two Phase 2 Multiple Ascending–Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer’s Disease

(2016) Florence Pasquier et al.   JOURNAL OF ALZHEIMERS DISEASE

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

(2016) Jeff Sevigny et al.   NATURE

A fresh perspective from immunologists and vaccine researchers: Active vaccination strategies to prevent and reverse Alzheimer's disease

(2015) Michael G. Agadjanyan et al.   Alzheimers & Dementia

Passive immunotherapy targeting amyloid-β reduces cerebral amyloid angiopathy and improves vascular reactivity

(2015) Kelly R. Bales et al.   BRAIN

Immunotherapeutic Approaches for Alzheimer’s Disease

(2015) Thomas Wisniewski et al.   NEURON

Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer’s disease

(2015) Martin R Farlow et al.   Alzheimers Research & Therapy

Amyloid-ß-directed immunotherapy for Alzheimer's disease

(2014) L. Lannfelt et al.   JOURNAL OF INTERNAL MEDICINE

Changes in the brain and plasma Aβ peptide levels with age and its relationship with cognitive impairment in the APPswe/PS1dE9 mouse model of Alzheimer’s disease

(2014) M. Izco et al.   NEUROSCIENCE

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

(2014) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Active immunotherapy options for Alzheimer’s disease

(2014) Bengt Winblad et al.   Alzheimers Research & Therapy

An MRI Rating Scale for Amyloid-Related Imaging Abnormalities with Edema or Effusion

(2013) F. Barkhof et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

MR Imaging Features of Amyloid-Related Imaging Abnormalities

(2013) J. Barakos et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Safety and Pharmacology of Ponezumab (PF-04360365) After a Single 10-Minute Intravenous Infusion in Subjects With Mild to Moderate Alzheimer Disease

(2013) Aaron H. Burstein et al.   CLINICAL NEUROPHARMACOLOGY

Safety and Pharmacology of a Single Intravenous Dose of Ponezumab in Subjects With Mild-to-Moderate Alzheimer Disease

(2013) Jaren W. Landen et al.   CLINICAL NEUROPHARMACOLOGY

Chronic Administration of an Aglycosylated Murine Antibody of Ponezumab Does Not Worsen Microhemorrhages in Aged Tg2576 Mice

(2012) Gary B. Freeman et al.   Current Alzheimer Research

N-Terminal pyroglutamate formation of Aβ38 and Aβ40 enforces oligomer formation and potency to disrupt hippocampal long-term potentiation

(2012) Dagmar Schlenzig et al.   JOURNAL OF NEUROCHEMISTRY

Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β

(2012) Justin M. Nussbaum et al.   NATURE

Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab

(2011) Susanne Ostrowitzki   ARCHIVES OF NEUROLOGY

Nitration of Tyrosine 10 Critically Enhances Amyloid β Aggregation and Plaque Formation

(2011) Markus P. Kummer et al.   NEURON

Neurotoxicity of Alzheimer's disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratio

(2010) Inna Kuperstein et al.   EMBO JOURNAL

The deposition of Aß40 in the brain is pathognomonic for Alzheimer-type dementia in Down syndrome

(2009) Pedro Pesini et al.   Alzheimers & Dementia

N-terminal truncated pyroglutamyl β amyloid peptide Aβpy3-42 shows a faster aggregation kinetics than the full-length Aβ1-42

(2009) Cristina D'Arrigo et al.   BIOPOLYMERS

Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders

(2009) Bruno Vellas et al.   Current Alzheimer Research

Amyloid Reduction by Amyloid-  Vaccination Also Reduces Mouse Tau Pathology and Protects from Neuron Loss in Two Mouse Models of Alzheimer's Disease

(2009) D. M. Wilcock et al.   JOURNAL OF NEUROSCIENCE

Amyloid β Protein: Aβ40 Inhibits Aβ42 Oligomerization

(2009) Megan M. Murray et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Vaccine adjuvants: Current challenges and future approaches

(2008) Jennifer H. Wilson-Welder et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

(2008) Clive Holmes et al.   LANCET